Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • Careers
  • Weekly

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. 19h ago

    CPHI Milan 2026: The White Drums With The Red Lid - Bart van Berkel

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Many in the pharma industry know CurTec for its white drums with the red lid, used to handle, store and contain the ingredients that go into medicines. CEO Bart van Berkel explains why pharma is the only industry CurTec focuses on. This week on Making It In Manufacturing, Harry Sloan sat down with Bart van Berkel, CEO of CurTec, at CPHI Milan 2026, where ARTO was the official podcast partner. In this episode, Bart covers: (01:00) What CurTec does: packaging that helps pharmaceutical companies, API and excipient suppliers and CMOs handle, store and contain the ingredients used to make medicines. (01:32) What carried over from aerospace: a highly regulated industry, long customer relationships, high standards of quality, and approval processes that take long for a good reason. (02:59) What makes a drum or pail pharmaceutical grade: easy to operate in suits and gloves, screw lids, GMP at the core, and designs that can dock to isolators. (04:16) Sustainability: taking material out, packaging that can be reused, and a redesigned drum with no handles or rubber gasket and a 30% CO2 reduction against CurTec's own products. (05:27) Why CurTec, opened in the 1950s in the Netherlands, built a factory in South Carolina and moved all its American customers to it. (07:35) Building greenfield to embed the CurTec culture of safety, compliance and cleanliness from the start, with a team of 30 and growing. (08:52) How pharma supply chains are shifting, and CurTec's commercial team in Asia working with suppliers of APIs and excipients. (10:01) Where CurTec could be in five years: very likely a facility in Asia, and new products that take it closer to pharma operations. (10:49) What he wants people to remember: CurTec is super dedicated to the pharma industry. Watch the full episode to hear why Bart wants anyone with a packaging problem to give CurTec a call. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Bart van Berkel LinkedIn: https://www.linkedin.com/in/bart-van-berkel-3824b3/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 01:00 What CurTec does 01:32 From aerospace to pharma 02:59 What makes packaging pharma grade 04:16 Sustainability and lighter drums 05:27 Why South Carolina 07:35 Building the CurTec culture 08:52 How pharma supply chains are changing 10:01 CurTec in five years 10:49 What to remember about CurTec #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PharmaPackaging #Sustainability #GMP #PharmaSupplyChain Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026: The White Drums With The Red Lid - Bart van Berkel

  2. 1d ago

    CPHI Milan 2026 Newsbeat: The Digital CMC Consortium Launches To Digitise CMC - Luke Guerrero

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto On the first day of CPHI Milan 2026, the Digital CMC Consortium launched: a pre-competitive, not-for-profit collaboration across the industry to digitise end-to-end CMC, founded with participation from companies including Novartis, Takeda and Thermo Fisher. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Luke Guerrero, one of the founding members and now Director of Operations of the Digital CMC Consortium, about the launch and what comes next. In this episode, Luke covers: (00:26) The launch: why biotechs, sponsors, CDMOs and consultancies have come together to solve the problems that can only be solved together. (01:18) Why sponsor to CDMO technology transfer is the first use case, and what a frictionless transfer would look like: as easy as moving to a new phone, instead of typing in every contact by hand. (02:55) How the consortium will turn standards into day-to-day practice: starting from the real workflow between sponsor and CDMO, building in pieces and iterating with members, and working with existing standards rather than replacing them. (04:27) What the consortium wants from the CPHI community: the varied perspectives of sponsors, CDMOs and equipment makers across the whole CMC value chain. Watch the full episode to hear how the Digital CMC Consortium plans to make tech transfer easier, so teams can focus on the real science. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Luke Guerrero LinkedIn: https://www.linkedin.com/in/lukeguerrero/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 00:22 The launch of the Digital CMC Consortium 01:06 Why tech transfer is the first use case 02:46 Turning shared standards into everyday practice 04:18 What the consortium wants from the CPHI community 05:05 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #CMC #TechTransfer #DigitalTransformation #CDMO #Pharma Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: The Digital CMC Consortium Launches To Digitise CMC - Luke Guerrero

  3. 2d ago

    CPHI Milan 2026 Newsbeat: Quotient Sciences Takes AI Into A Clinical Trial - Andy Lewis

    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Quotient Sciences has announced interim results from its AI-driven clinical trial. After three years developing AI for formulation development, with 30 to 50% time savings, Quotient took the approach into the clinic to see if it could also learn how a formulation's composition relates to its performance in people. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Andy Lewis, Chief Scientific Officer of Quotient Sciences, about the results and what they could mean for drug development. In this episode, Andy covers: (00:25) The interim results: the AI appears to have learned the link between composition and in vivo performance after testing just three prototypes, which could reduce the clinical testing a product needs. (01:25) How the algorithm learned: active learning with Bayesian optimisation, starting untrained, trained first on in vitro data and then on the emerging clinical data, with a safety committee reviewing every formulation it requested. When the team changed the target to rule out luck, it hit that one too. (03:27) What it could mean for modified release products: fewer formulation screens, faster clinical development, and an in silico model of the drug product, like a digital twin, that could support scale-up and post-approval changes such as a change of site. (05:05) What drug developers at CPHI Milan are most excited about: a first look at the pharmacokinetic data, and how the tool's visualisations map onto quality by design. Watch the full episode to hear how Quotient Sciences is using AI to save time at every step of drug product development. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Andy Lewis LinkedIn: https://www.linkedin.com/in/andylewis1/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 00:16 Quotient's interim clinical trial results 01:25 How the algorithm learned from each dosing period 03:27 What it could mean for modified release development 05:05 What drug developers at CPHI are excited about 06:08 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #AI #MachineLearning #FormulationDevelopment #DrugDevelopment #ClinicalTrials Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: Quotient Sciences Takes AI Into A Clinical Trial - Andy Lewis

  4. 3d ago

    CPHI Milan 2026: From 500 Million To A Billion Units - Ankit Gupta

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto A year ago, InstaPill was adding a new block to take its capacity in India to 500 million units. Now CEO Ankit Gupta plans a new greenfield site to double that to a billion, able to handle everything that is ODT. This week on Making It In Manufacturing, Harry Sloan caught up again with Ankit Gupta, CEO of InstaPill, at CPHI Milan 2026, where ARTO was the official podcast partner. In this episode, Ankit covers: (01:12) Why InstaPill is planning a new greenfield site in India, on about 18 acres of land, modular so capacity can grow with demand. (02:35) The move to a CDMO and B2B model, built on its two strengths: development and manufacturing. (03:55) What sets InstaPill apart: transparency and flexibility, with projects partners typically do in 9 to 10 months delivered in 3 to 6. (05:01) Where a US site fits: the bulk of its partners are in the US, and the plan stays on track for when partners need it. (06:22) What to ask him about next year: more visible partnerships and more products reaching the market. Watch the full episode to hear why Ankit wants partners to think of InstaPill as the company that can do everything that is possible on ODT. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Ankit Gupta LinkedIn: https://www.linkedin.com/in/reachankit/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 01:12 Doubling to a billion units 02:35 From own products to CDMO partner 03:55 Transparency and flexibility 05:01 The plan for the US 06:22 What to watch for next year #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ODT #CDMO #DrugDelivery #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026: From 500 Million To A Billion Units - Ankit Gupta

  5. Oct 29

    CPHI Milan 2026: Taking Manufacturing Out Of The Dark Ages - Sheena Dempsey

    Drug discovery and clinical development have all benefited from the COVID era and the AI era, but for Sheena Dempsey, manufacturing is still stuck somewhat in the dark ages. As President and CEO of CAI, she wants to drive automation and acceleration that get medicines into the hands of patients faster. This week on Making It In Manufacturing, Elliot Payne sat down with Sheena Dempsey, President and CEO of CAI, the global consultancy for commissioning and qualification and operational readiness, at CPHI Milan 2026, where ARTO was the official podcast partner. In this episode, Sheena covers: (00:57) What CAI does: commissioning and qualification, operational readiness and operational excellence for most of the top pharmaceutical companies, with about 750 people across North America, Europe and APAC. (02:06) The new partnership with JLL Partners, and her three to five year plan to grow CAI, organically and inorganically, in footprint and in services. (03:13) What drew her to CAI after building life sciences practices in professional services, and why she calls herself a global misfit. (04:44) Getting experienced people and Gen Z and Gen Alpha digital natives working well together: the goals are the same, and it takes leadership, change management and training on both sides. (06:58) Why paper in manufacturing plants is unacceptable today, and why digitisation lends itself to compliance and stops knowledge being lost. (07:43) What CAI looks for in new people, and managing talent as a portfolio, from trade schools and internships to graduates. (10:03) Why CAI is building its own trade school pipeline for aseptic manufacturing, where the demand for talent is enormous. (12:06) What success in 2027 looks like: the right balance of skills, global teams built around a customer's need, and the excitement of a plant's first batch. (13:31) The one thing she would remove from pharma manufacturing: its deeply held resistance to change. (14:23) Why she is optimistic: pockets of real innovation at particular sites, led by site heads and change agents. Watch the full episode to hear why Sheena believes the inflection point manufacturing needs is already in play. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Sheena Dempsey LinkedIn: https://www.linkedin.com/in/sheena-dempsey-b693575/ Elliot Payne LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/ Timestamps: 00:00 Introduction 00:57 What CAI does 02:06 The JLL Partners partnership 03:13 Why Sheena chose CAI 04:44 Bringing generations together 06:58 Taking paper out of manufacturing 07:43 What CAI looks for in talent 10:03 Building a trade school pipeline 12:06 What success looks like in 2027 13:31 One thing to remove from the industry 14:23 Reasons for optimism #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Commissioning #Qualification #Digitalisation #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026: Taking Manufacturing Out Of The Dark Ages - Sheena Dempsey

  6. Oct 28

    The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel

    This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk. In this panel: - Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill - How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk - How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two - Fixed platforms with flexible indications, and when one facility can serve many - The latest build, buy or partner calls each CEO has made - Data or instinct: how they decide where to invest next - The one thing each of them would remove from pharma manufacturing Be sure to watch to the end for the quickfire round. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto 🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@artotalent Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4 The panel : Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/ Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/ Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/ Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/ Timestamps: 0:00 Intro 0:15 Welcome to the CEO’s Weekly Challenge 0:50 How do you weigh capacity risk against indication risk? 6:50 ten23 health: the science, not the disease 9:06 Do biosimilars take indication risk out? 10:56 Curapath’s ALS customer: from 16 conjugates to four 12:28 Fixed platform, flexible indications 15:31 Fast, flexible capacity: real or a marketing ploy? 23:29 Biosimilars: flexibility or analytical rigour? 26:03 Can one facility serve many indications and be best in class? 28:29 The latest build, buy or partner call 33:35 Data or instinct? 40:34 Quickfire: one thing to remove from pharma manufacturing #MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery Hosted on Acast. See acast.com/privacy for more information.

    The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel

  7. Oct 27

    CPHI Milan 2026 Newsbeat: 53Biologics Takes Fill And Finish Fully In House - Javier Santos

    53Biologics is adding new lyophilisation equipment and an isolator to its facilities, completing its fill and finish capabilities so the company is fully end to end. That means the small batches first clinical trials need can stay under one roof. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Javier Santos, Business Developer at 53Biologics, about the company's new in-house lyophilisation and what it means for customers' clinical programmes. In this episode, Javier covers: (00:33) 53Biologics' new lyophilisation equipment and isolator, which complete its fill and finish capabilities and make the company end to end, in line with its philosophy. (01:05) Why the small batches needed for first clinical trials are so hard to place with outside fill and finish suppliers, and how bringing the work in house removes that bottleneck, especially in phase one. (02:14) How keeping every step with one partner makes customers' projects quicker and more efficient, with no extra contracts and no separate providers' timelines to manage. (03:13) What his conversations at CPHI have confirmed: clients across many projects are asking for the same small batches, so the capability needs to be in place. Watch the full episode to hear why Javier sees having everything under one roof as the answer to the small-batch bottleneck. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Javier Santos LinkedIn: https://www.linkedin.com/in/javier-santos-aberturas-96b7a45a/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 00:52 Why small clinical batches need in-house fill and finish 01:58 Simpler projects, everything in one place 02:58 What CPHI conversations have confirmed 03:52 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #FillAndFinish #Lyophilisation #Biologics #CDMO Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: 53Biologics Takes Fill And Finish Fully In House - Javier Santos

  8. Oct 27

    "I Want Regulators To Say There's A Safer Alternative" | 4basebio's 10-Year Plan

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. This week on Making It In Manufacturing, Thomas McMann sat down with Dr Amy Walker, CEO of 4basebio. In this episode, Amy covers: • Why DNA has been made the same way for 50 years, and what changes when you take the bacteria out of the process entirely. • How 4basebio's enzymatic platform works, and why it cuts GMP grade DNA from a 6 to 9 month wait down to under 12 weeks. • What it was actually like joining as the company's first employee, when 4basebio was an empty building on an industrial estate outside Cambridge. • The funding headwinds of the last two years, what happens when a client loses their NIH funding overnight, and how they diversified the client base around it. • Why she believes synthetic DNA disrupting plasmid is a question of when rather than if, and what she wants regulators saying about it in ten years' time. Worth watching if you work anywhere near cell and gene therapy, mRNA, viral vectors or DNA supply. Even if plasmid isn't your day to day, it's a clear look at how an established manufacturing process gets displaced, and what it takes to get conservative buyers to switch. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/channel/UCkoSWF_xqX4i9OIkX4pGaxQ Dr Amy Walker LinkedIn: https://www.linkedin.com/in/amy-walker-4a9785154/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b Timestamps: 00:00 Introduction 01:35 What 4basebio does 02:10 Operating as a CDMO 02:48 Why plasmid DNA hasn't changed in 50 years 04:09 The safety benefits of removing bacteria 04:49 Lowering the dose required 05:23 From 6 to 9 months down to under 12 weeks 05:36 Personalised cancer vaccines 05:53 Touchlight and why there is so little competition 06:25 How mRNA vaccines changed the conversation 07:36 TruePrime and opDNA explained 08:44 Clean rooms no bigger than a podcast booth 09:46 Why cell free is the real difference 10:48 Joining 4basebio as its first employee 12:01 Head of Discovery to COO to CEO 13:09 Balancing the science and the commercial 14:14 The funding headwinds of the last two years 15:37 GMP certification and getting into the clinic 17:00 Persuading big pharma to switch 17:47 The regulatory objection 19:54 The Genezen partnership 20:32 "There was nothing to see. It was an empty building" 23:31 The advantage of having worn every hat 24:41 Where the strongest growth is coming from 26:41 The case for vertical integration 28:46 Sustainability 29:44 Where 4basebio is in ten years 30:49 Quickfire questions #MakingItInManufacturing #ARTOTalent #4basebio #SyntheticDNA #PlasmidDNA #CellAndGeneTherapy #mRNA #ViralVectors #CDMO #Biomanufacturing Hosted on Acast. See acast.com/privacy for more information.

    "I Want Regulators To Say There's A Safer Alternative" | 4basebio's 10-Year Plan
See All (56)

About

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Information